• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.

作者信息

Bavendiek Udo, Aguirre Davila Lukas, Koch Armin, Bauersachs Johann

机构信息

Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 01, 30625 Hannover, Germany.

Department of Biostatistics, Hannover Medical School, Carl-Neuberg-Str. 01, 30625 Hannover, Germany.

出版信息

Eur Heart J. 2017 Jul 14;38(27):2095-2099. doi: 10.1093/eurheartj/ehw577.

DOI:10.1093/eurheartj/ehw577
PMID:28065909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5837211/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/89502bf9d94f/ehw577f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/86e16f8c2c19/ehw577f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/7d597a0b9c76/ehw577f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/89502bf9d94f/ehw577f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/86e16f8c2c19/ehw577f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/7d597a0b9c76/ehw577f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fec8/5837211/89502bf9d94f/ehw577f3.jpg

相似文献

1
Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.假设与证据：地高辛用于心房颤动和心力衰竭的案例
Eur Heart J. 2017 Jul 14;38(27):2095-2099. doi: 10.1093/eurheartj/ehw577.
2
Digoxin - don't dismiss it just yet.地高辛——先别急着摒弃它。
Eur J Cardiovasc Nurs. 2017 Aug;16(6):464-465. doi: 10.1177/1474515115612272. Epub 2015 Oct 13.
3
Digoxin.地高辛
Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):251-66. doi: 10.1053/pcad.2002.31591.
4
Use of digoxin for heart failure and atrial fibrillation in elderly patients.地高辛在老年患者心力衰竭和心房颤动中的应用。
Am J Geriatr Pharmacother. 2010 Oct;8(5):419-27. doi: 10.1016/j.amjopharm.2010.10.001.
5
Is there a role for digoxin in atrial fibrillation without heart failure?地高辛在无心力衰竭的心房颤动中是否有作用？
Cardiol J. 2009;16(5):483-6.
6
[Digoxin and atrial fibrillation in 2016].[2016年的地高辛与心房颤动]
Rev Med Suisse. 2016 Oct 19;12(535):1758-1760.
7
Effect of Digoxin Use Among Medicaid Enrollees With Atrial Fibrillation.地高辛在医疗补助计划覆盖的心房颤动患者中的使用效果。
Circ Arrhythm Electrophysiol. 2017 May;10(5):e004573. doi: 10.1161/CIRCEP.116.004573.
8
Digoxin: The good and the bad.地高辛：利与弊。
Trends Cardiovasc Med. 2016 Oct;26(7):585-95. doi: 10.1016/j.tcm.2016.03.011. Epub 2016 Mar 31.
9
Mortality in heart failure with atrial fibrillation: Role of digoxin and diuretics.心力衰竭伴心房颤动患者的死亡率：地高辛和利尿剂的作用。
Eur J Clin Invest. 2018 Nov;48(11):e13014. doi: 10.1111/eci.13014. Epub 2018 Aug 23.
10
Digoxin mortality in heart failure and atrial fibrillation.
Eur Heart J. 2015 Aug 7;36(30):1944-5.

引用本文的文献

1
Sex differences in diagnosis and treatment of heart failure: toward precision medicine.心力衰竭诊断与治疗中的性别差异：迈向精准医学
Korean J Intern Med. 2025 Mar;40(2):196-207. doi: 10.3904/kjim.2024.338. Epub 2025 Mar 1.
2
Digoxin and exercise effects on skeletal muscle Na,K-ATPase isoform gene expression in healthy humans.地高辛和运动对健康人体骨骼肌 Na,K-ATPase 同工型基因表达的影响。
Exp Physiol. 2024 Nov;109(11):1909-1921. doi: 10.1113/EP091962. Epub 2024 Sep 2.
3
A century of exercise physiology: effects of muscle contraction and exercise on skeletal muscle Na,K-ATPase, Na and K ions, and on plasma K concentration-historical developments.

本文引用的文献

1
Digoxin: The good and the bad.地高辛：利与弊。
Trends Cardiovasc Med. 2016 Oct;26(7):585-95. doi: 10.1016/j.tcm.2016.03.011. Epub 2016 Mar 31.
2
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study.负面他汀类药物相关新闻报道降低了他汀类药物的持久性，并增加了心肌梗死和心血管死亡率：一项全国范围的前瞻性队列研究。
Eur Heart J. 2016 Mar 14;37(11):908-916. doi: 10.1093/eurheartj/ehv641. Epub 2015 Dec 1.
3
Atrial fibrillation in heart failure: what should we do?
一个世纪的运动生理学：肌肉收缩和运动对骨骼肌 Na，K-ATP 酶、Na 和 K 离子以及血浆 K 浓度的影响-历史发展。
Eur J Appl Physiol. 2024 Mar;124(3):681-751. doi: 10.1007/s00421-023-05335-9. Epub 2024 Jan 11.
4
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.韩国心力衰竭管理指南：治疗
Int J Heart Fail. 2023 Apr 10;5(2):66-81. doi: 10.36628/ijhf.2023.0011. eCollection 2023 Apr.
5
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.韩国心力衰竭管理学会心力衰竭指南：治疗
Korean Circ J. 2023 Apr;53(4):217-238. doi: 10.4070/kcj.2023.0047.
6
Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial.基于 DIGIT-HF 试验数据的心力衰竭患者地高辛简单、安全的剂量调整。
Clin Res Cardiol. 2023 Aug;112(8):1096-1107. doi: 10.1007/s00392-023-02199-z. Epub 2023 Apr 22.
7
Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository.地高辛与COVID-19心力衰竭患者的标准治疗：来自美国军事卫生系统（MHS）数据存储库的数据分析
Drugs Real World Outcomes. 2023 Jun;10(2):299-307. doi: 10.1007/s40801-023-00360-8. Epub 2023 Mar 18.
8
Effect of digoxin on all-cause and cardiovascular mortality in patients with atrial fibrillation with and without heart failure: an umbrella review of systematic reviews and 12 meta-analyses.地高辛对伴有或不伴有心力衰竭的心房颤动患者全因和心血管死亡率的影响：系统评价和 12 项荟萃分析的伞状评价。
Eur J Clin Pharmacol. 2023 Apr;79(4):473-483. doi: 10.1007/s00228-023-03470-y. Epub 2023 Mar 6.
9
Oral digoxin effects on exercise performance, K regulation and skeletal muscle Na ,K -ATPase in healthy humans.健康人体中口服地高辛对运动表现、钾调节和骨骼肌钠钾-ATP 酶的影响。
J Physiol. 2022 Aug;600(16):3749-3774. doi: 10.1113/JP283017. Epub 2022 Aug 2.
10
Cardiac Oxidative Signaling and Physiological Hypertrophy in the Na/K-ATPase α1α2 Mouse Model of High Affinity for Cardiotonic Steroids.心脏氧化信号和生理肥大在高亲和力心脏毒素甾体的 Na/K-ATPase α1α2 小鼠模型中。
Int J Mol Sci. 2021 Mar 27;22(7):3462. doi: 10.3390/ijms22073462.
心力衰竭中的心房颤动：我们该怎么做？
Eur Heart J. 2015 Dec 7;36(46):3250-7. doi: 10.1093/eurheartj/ehv513. Epub 2015 Sep 28.
4
Rate-control treatment and mortality in atrial fibrillation.房颤的心率控制治疗与死亡率。
Circulation. 2015 Oct 27;132(17):1604-12. doi: 10.1161/CIRCULATIONAHA.114.013709. Epub 2015 Sep 17.
5
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data.地高辛的安全性和有效性：观察性和对照试验数据的系统评价与荟萃分析
BMJ. 2015 Aug 30;351:h4451. doi: 10.1136/bmj.h4451.
6
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort.当代房颤队列患者中地高辛的使用及后续结局
J Am Coll Cardiol. 2015 Jun 30;65(25):2691-8. doi: 10.1016/j.jacc.2015.04.045.
7
Digoxin-associated mortality: a systematic review and meta-analysis of the literature.地高辛相关死亡率：文献系统评价和荟萃分析。
Eur Heart J. 2015 Jul 21;36(28):1831-8. doi: 10.1093/eurheartj/ehv143. Epub 2015 May 4.
8
Digoxin use in atrial fibrillation: a critical reappraisal.地高辛在心房颤动中的应用：一项批判性重新评估。
Lancet. 2015 Jun 13;385(9985):2330-2. doi: 10.1016/S0140-6736(14)62301-1. Epub 2015 Mar 6.
9
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).地高辛在伴有不良心血管结局的心房颤动患者中的应用：利伐沙班每日一次口服直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的临床试验（ROCKET AF）的回顾性分析。
Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.
10
Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study.当代房颤患者中与地高辛相关的死亡率增加：TREAT-AF研究的结果
J Am Coll Cardiol. 2014 Aug 19;64(7):660-8. doi: 10.1016/j.jacc.2014.03.060.